IOVA focuses on TIL therapy in Metastatic Melanoma and has a relatively long cash runway. IOVA is presently enrolling a Ph2 trial in Metastatic Melanoma If the bloom continues to fade on CART-T therapies, the equity market may pay more attention to TIL At present the burn rate, IOVA's cash runway extends into 2022.